Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19

Jun 12 2020 , India

Start a topic

Coronavirus disease 2019 (Covid-19) may disproportionately affect people with
cardiovascular disease. Concern has been aroused regarding a potential harmful
effect of angiotensin-converting–enzyme (ACE) inhibitors and angiotensin-receptor
blockers (ARBs) in this clinical context.
Using an observational database from 169 hospitals in Asia, Europe, and North
America, we evaluated the relationship of cardiovascular disease and drug therapy
with in-hospital death among hospitalized patients with Covid-19 who were admitted
between December 20, 2019, and March 15, 2020, and were recorded in the
Surgical Outcomes Collaborative registry as having either died in the hospital or
survived to discharge as of March 28, 2020.

View as PDF

Share Your Views

By registering, using and interacting on this website, you represent and warrant that you are a registered medical practitioner under the governing law of the country you reside or represent and are lawful citizens